Skip to main content

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Single- Dose Ebola Vaccine Developed

    Researchers have developed a quick-acting Ebola vaccine that is both safe and effective with a single dose against the strain of the virus that killed thousands of people in West Africa last year. “These findings may pave the way for the identification and manufacture of safer, single dose, high efficiency vaccines to combat current and future Ebola outbreaks,” said Thomas Geisbert, from the University of Texas Medical Branch at Galveston.

  • Teva provides additional detail on proposed acquisition of Mylan

    (Business Wire India); Teva Pharmaceutical Industries Ltd. has announced that an updated investor presentation in connection with its proposed combination with Mylan N.V. is available on the Investor Relations section of the Company’s website and will be filed with the Securities and Exchange Commission (“SEC”).

  • Breast cancer vaccines and silicon microparticles together may work better

    The effectiveness of cancer vaccines could be dramatically boosted by first loading the cancer antigens into silicon microparticles, report scientists from Houston Methodist and two other institutions in an upcoming Cell Reports (early online).

  • EU received marketing approval for Sanofi Toujeo to treat diabetes in adults

    The European Commission has granted marketing authorization in Europe for Sanofi's Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults. Its significant milestone for Sanofi. This gives people with diabetes and their physicians a new option to manage their condition.

  • aTyr Pharma's Resolaris receives US FDA orphan drug status to treat FHSD

    aTyr Pharma, a biotherapeutics company engaged in the discovery and development of physiocrine-based therapeutics to address rare diseases, announced  that Resolaris has been granted Orphan Drug designation by the US Food and Drug Administration (FDA) for the treatment of facioscapulohumeral muscular dystrophy (FSHD).  Resolaris, an investigational new drug,  is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component.

  • Pregnancy glow has Scientific proof: Report

    Women glow during pregnancy because they share the blood of their young foetus which has a rejuvenating effect on the mother which regenerates tissue and slow down the ageing process, according to a report. The oft-used phrase “pregnancy glow” seems to now have some basis in science because pregnancy helps regenerate tissue and slow down the ageing process. The effect occurs because of the shared blood between mother and child.

  • Govt Nod to MOU with mauritius on Cooperation in Traditional medicine

    The government gave its approval for signing of an agreement with Mauritius on cooperation in traditional medicine systems and homoepathy. In a meeting, the Union cabinet chaired by Prime Minister Narendra Modi gave its approval for the memorandum of understanding between the two countries to enhance bilateral cooperation in areas of traditional medicine including medicinal plants, Telecom Minister Ravi Shankar Prasad said told reporters.

  • Pfizer revenues reduced by 4.3% to $10,864 million from $11,353 million, 2015 forecasts

    Pfizer has posted lower revenue during the first quarter ended March 2015. This is due to the loss of exclusivity and immediate multi-source generic competition for Celebrex in the US and termination of the Spiriva co-promotion collaboration in certain countries. Its revenue reduced by 4.3 per cent to $10,864 million from $11,353 million in the corresponding period of last year. Pfizer  net profit improved marginally by 2 per cent to $2,376 million from $2,329 million.

  • Indian pharma companies received US FDA marketing nod for generic aripiprazole

    Three Indian pharmaceutical companies, namely Alembic Pharmaceuticals, Hetero Labs and Torrent Pharmaceuticals have get the US Food and Drug Administration (FDA) approval for generic versions of Abilify (aripiprazole). Aripiprazole is an atypical antipsychotic drug approved to treat schizophrenia and bipolar disorder.   Teva Pharmaceuticals has also get  similar approval.

     

Subscribe to Pharma News

Search this website